Member Info for Umaz

And this was crossed on Friday, so the HUGE buy mystery solved.

Peel Hunt buying for the big US buyer people are talking about at adv?

So far James is looking right today :-)

Ah, got it.

Sav, where do you get the buy and sell orders info from? I can only see the following.

# of Trades 400

Vol Sold 792,581

Vol Bought 332,992

Check COPL.

Directors have to be careful what they say, else there are legal consequences.

Will be around £1 per share...... Can P140 be the game changer?

pps mcap

09.90p 50m

39.78p 200m

79.57p 400m

99.46p 500m

Please share the link Maidit.

I think (rather hope) the deal will be a combination of Upfront payment and Royalties (a share of future sales revenue) - its the structure of the deal where Ketan's experience has been called for. Again, its a theory and I might be wrong.

Sometimes, buyers/investors want their representative to be on the board, this doesn't seem to be the case reading into Tim's wordings.

Https://www.linkedin.com/in/ketan-patel-cfa-50157014/

My theory is that a licence/strategic deal with an equity kicker is imminent. IMM is emphasising P140 and “future strategic partnerships and commercial deals” in the appointment wording. A credible NED with healthcare investment networks can help catalyse or validate a partnering process that may include an equity component from a strategic or its funders.

Tim also ruled out "no placing/fund raising" inclines more towards a strategic transaction, rather than a raise.

“Licence / Strategic Deal with an Equity Kicker” refers to when a biotech company (like ImmuPharma) enters into a commercial agreement with a larger company — usually a pharma, biotech, or regional distributor — involving one of its drug candidates or technologies.

That deal might include:

Upfront payment (cash to IMM immediately)

Milestone payments (on development, regulatory, or sales targets)

Royalties (a share of future sales revenue)

R&D collaboration (shared funding or expertise)

Essentially, it’s a monetisation deal — a way to turn IMM’s intellectual property into funding and commercial traction without raising money directly from the market.

If you look the RNS, there are two independent statements from Tim. It seconds my theory that Ketan's primary focus will be to provide expert guidance to IMM in the negotiations with the strategic partner. And then also, bring on more II (which can ofcourse be via placing but not necessarily at a discount as we have seen many times for many companies e.g. Fiinu).

1. Importantly, Ketan's appointment, at this time, brings a unique perspective to the Board, as we concentrate on future strategic partnerships and commercial deals across our product portfolio and in particular, our lead auto-immune platform technology, P140.

2. In addition, Ketan's investment management experience will greatly assist us in expanding our institutional shareholder base."

Thanks to the recent share price hike, IMM has got enough funds from the Lanstead deal to take then through the deal.......

Agreed. Added more today....

A whooping £48.75k buy!!!!

Time will tel OTM. Hope it turns out well for everyone.

IMM has got* enough funds

I also wanted to add that there are two independent statements from Tim. It seconds my theory that Ketan's primary focus will be to provide expert guidance to IMM in the negotiations with the strategic partner. And then also, bring on more II (which can ofcourse be via placing but not necessarily at a discount as we have seen many times for many companies e.g. Fiinu).

1. Importantly, Ketan's appointment, at this time, brings a unique perspective to the Board, as we concentrate on future strategic partnerships and commercial deals across our product portfolio and in particular, our lead auto-immune platform technology, P140.

2. In addition, Ketan's investment management experience will greatly assist us in expanding our institutional shareholder base."

Thanks to the recent share price hike, IMM has not enough funds from the Lanstead deal to take then through the deal.......

Https://www.linkedin.com/in/ketan-patel-cfa-50157014/ -

My theory is that a licence/strategic deal with an equity kicker is imminent. IMM is emphasising P140 and “future strategic partnerships and commercial deals” in the appointment wording. A credible NED with healthcare investment networks can help catalyse or validate a partnering process that may include an equity component from a strategic or its funders. Note the word "Independent" in the announcement.

Tim also ruled out "no placing/fund raising" inclines more towards a strategic transaction, rather than a raise. Fingers crossed.

“Licence / Strategic Deal with an Equity Kicker” explained

1. Licence or strategic deal

This refers to when a biotech company (like ImmuPharma) enters into a commercial agreement with a larger company — usually a pharma, biotech, or regional distributor — involving one of its drug candidates or technologies.

That deal might include:

Upfront payment (cash to IMM immediately)

Milestone payments (on development, regulatory, or sales targets)

Royalties (a share of future sales revenue)

R&D collaboration (shared funding or expertise)

Essentially, it’s a monetisation deal — a way to turn IMM’s intellectual property (like P140 for lupus) into funding and commercial traction without raising money directly from the market.

At 10:29am, the spread was 33.30 - 34.45, so could well be a buy :-)

Vol Sold 2,092,515

Vol Bought 3,227,084

Tells it all.

Savs1907 on a humanitarian agenda to save fellow investors, what a noble gesture!

Vol Sold 1,925,558

Vol Bought 1,933,469

The gap was more than a million in the morning. So buying catching up (or allowed now) it seems.